Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon secretion. It is unique among DPP-4 inhibitors for its primary biliary excretion, requiring no dose adjustments for renal or hepatic impairment.
## Primary Indications
Type 2 diabetes mellitus (adjunct to diet and exercise to improve glycemic control).
## Adult Dosing
Standard dose: 5 mg orally once daily.
Maximum dose: 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients <18 years of age. Use is generally not recommended in pediatric populations.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
* **Concomitant use with strong CYP3A4/P-gp inducers (e.g., rifampin):** Decreased efficacy may occur; consider alternative antihyperglycemic agents if glycemic control is inadequate.
## Contraindications
* History of serious hypersensitivity reactions to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or diabetic ketoacidosis (not indicated).
## Adverse Effects
* **Common:** Nasopharyngitis, upper respiratory tract infection.
* **Serious:** Pancreatitis (including fatal), severe and disabling arthralgia, bullous pemphigoid, hypoglycemia (when used with insulin or secretagogues).
## Key Drug Interactions
* **Strong CYP3A4/P-glycoprotein inducers:** (e.g., rifampin, carbamazepine, phenytoin) May significantly reduce linagliptin plasma concentrations.
* **Insulin/Insulin Secretagogues:** (e.g., sulfonylureas) Increased risk of hypoglycemia; consider dose reduction of the secretagogue.
## Monitoring
* **Glycemic Control:** HbA1c (typically every 3–6 months), periodic fasting blood glucose.
* **Clinical:** Observe for signs/symptoms of pancreatitis (persistent severe abdominal pain), severe joint pain, or skin blistering/erosions.
## Clinical Pearls
* **No renal dose adjustment:** Linagliptin is the only DPP-4 inhibitor that does not require renal dose modification, making it a preferred option for patients with chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Pancreatitis:** If pancreatitis is suspected, discontinue linagliptin promptly and initiate appropriate management; do not restart if confirmed.
* **Heart Failure:** While not strictly contraindicated, use caution in patients with known heart failure (some DPP-4 inhibitors have shown increased hospitalization risk).
***
*Disclaimer: This information is for educational purposes only. Drug information is subject to change based on new clinical evidence and local institutional guidelines. Always verify current prescribing information, clinical trial data, and hospital-specific protocols before finalizing a drug regimen or order.*
